Dendreon Corporation
(Other OTC/NBB : DNDN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
ISRGIntuitive Surgical, Inc.
1.03%526.672.4%$403.92m
MDTMedtronic PLC
-0.01%88.410.6%$375.48m
ABTAbbott Laboratories
-0.26%63.620.8%$331.77m
ABMDABIOMED, Inc.
-0.26%424.903.3%$305.99m
ALGNAlign Technology, Inc.
1.96%377.586.3%$289.95m
TMOThermo Fisher Scientific Inc.
0.57%217.301.0%$264.21m
BDXBecton, Dickinson and Company
0.23%247.541.1%$249.69m
BSXBoston Scientific Corporation
0.61%33.931.1%$196.18m
SYKStryker Corporation
1.37%175.231.3%$170.51m
EWEdwards Lifesciences Corporation
1.71%152.851.2%$168.10m
BAXBaxter International Inc.
0.76%75.311.7%$162.73m
COOCooper Companies, Inc.
0.31%248.762.2%$104.10m
WATWaters Corporation
0.33%198.293.4%$101.43m
ZBHZimmer Biomet Holdings, Inc.
-0.10%112.131.7%$98.65m
IDXXIDEXX Laboratories, Inc.
1.87%247.363.7%$93.20m

Company Profile

Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.